Gå direkt till huvudinnehållet

P/S-Homocystein

Senast uppdaterad: Senast reviderad:
Sakkunnig:

  1. Hultberg B, Isaksson A, Nilsson K, Gustafson L. Homocystein och metylmalonsyra markörer för kobalamin-/folatstatus. Läkartidningen  2000; 97: 4131-6.
  2. Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Rev Cardiovasc Ther. 2018 Aug;16(8):559-565 . pmid:29979619 PubMed  
  3. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37485 individuals. Arch Intern Med 2010; 170: 1622-31. PubMed  
  4. Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008; 300: 795-804. Journal of the American Medical Association  
  5. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612. Published 2017 Aug 17. PMID:28816346. PubMed  
  6. Läkemedelsverket (2014). Aterosklerotisk hjärt-kärlsjukdom. (Hämtad 2022-01-20).
  7. UpToDate. Overview of homocysteine. Last updated Dec 06, 2021 (Hämtad 22-01-20). www.uptodate.com  
  8. van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033-41. New England Journal of Medicine  
  • Anders Kallner, docent och fd överläkare, Karolinska universitetslaboratoriet, Karolinska universitetssjukhuset